Behzad Aghazadeh - 24 Jul 2026 Form 4 Insider Report for Scribe Therapeutics, Inc. (SCTX)

Reporting relationship: Director, Other*, 10%+ Owner
Issuer ticker: SCTX
Reported as of: 24 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jul 2026, 21:30:16 UTC
Prior SEC filing: 23 Jul 2026
Source filing: View source filing
Reporting owner signature: Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer

Key filing fact

Behzad Aghazadeh filed Form 4 for Scribe Therapeutics, Inc. (SCTX) on 28 Jul 2026.

Key facts

This page summarizes Behzad Aghazadeh's Form 4 filing for Scribe Therapeutics, Inc. (SCTX).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 28 Jul 2026, 21:30.

Change

Previous filing in this sequence was filed on 23 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001701815 Primary reporting owner

Aghazadeh Behzad

Relationship: Director, Other*, 10%+ Owner
Address: C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK
Signature: Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer
Signature date: 28 Jul 2026

CIK 0001633313

Avoro Capital Advisors LLC

Relationship: Director, Other*, 10%+ Owner
Address: 110 GREENE STREET, SUITE 800, NEW YORK
Signature: Avoro Ventures LLC, by: /s/ Scott Epstein, its Chief Operating Officer Chief Compliance Officer
Signature date: 28 Jul 2026

CIK 0001879253

Avoro Ventures LLC

Relationship: Director, Other*
Address: 110 GREENE STREET, SUITE 800, NEW YORK
Signature: /s/ Behzad Aghazadeh
Signature date: 28 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SCTX transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value
Shares: +2,333,333
Change %: +334%
Price: $15.00^*
Shares after: 3,030,983
Date: 24 Jul 2026
Ownership: See footnotes
Footnotes: F1, F4, F5, F6

SCTX transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value
Shares: +2,333,333
Change %: +334%
Price: $15.00^*
Shares after: 3,030,983
Date: 24 Jul 2026
Ownership: See footnotes
Footnotes: F1, F4, F5, F6

SCTX transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value
Shares: +2,333,333
Change %: +334%
Price: $15.00^*
Shares after: 3,030,983
Date: 24 Jul 2026
Ownership: See footnotes
Footnotes: F1, F4, F5, F6

SCTX transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value
Shares: +50,000
Change %: +1.6%
Price: $22.31^*
Shares after: 3,080,983
Date: 24 Jul 2026
Ownership: See footnotes
Footnotes: F2, F4, F5, F6

SCTX transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value
Shares: +50,000
Change %: +1.6%
Price: $22.31^*
Shares after: 3,080,983
Date: 24 Jul 2026
Ownership: See footnotes
Footnotes: F2, F4, F5, F6

SCTX transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value
Shares: +50,000
Change %: +1.6%
Price: $22.31^*
Shares after: 3,080,983
Date: 24 Jul 2026
Ownership: See footnotes
Footnotes: F2, F4, F5, F6

SCTX transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value
Shares: +7,905
Change %: +0.26%
Price: $18.25^*
Shares after: 3,088,888
Date: 28 Jul 2026
Ownership: See footnotes
Footnotes: F2, F3, F4, F5, F6

SCTX transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value
Shares: +7,905
Change %: +0.26%
Price: $18.25^*
Shares after: 3,088,888
Date: 28 Jul 2026
Ownership: See footnotes
Footnotes: F2, F3, F4, F5, F6

SCTX transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value
Shares: +7,905
Change %: +0.26%
Price: $18.25^*
Shares after: 3,088,888
Date: 28 Jul 2026
Ownership: See footnotes
Footnotes: F2, F3, F4, F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds").

Footnote F2

The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.

Footnote F3

Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund.

Footnote F4

The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.

Footnote F5

Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).

Footnote F6

The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.

SEC remarks

Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.